paget's%20bone%20disease
PAGET'S BONE DISEASE
Paget's bone disease, also known as osteitis deformans, is characterized by a significant increase in bone resorption and turnover in localized parts of the skeleton causing enlargement and thickening of the bone that is disordered and architecturally unstable.
The prevalence increases with age, with men and women affected equally.
Genetic factors and/or viral infection may play a role in the etiology.
May affect one bone (monostotic) or several bones (polyostotic).
By decreasing frequency, involved bones may include pelvic bone and sacrum, spine, skull and femur, tibia, humeri and clavicles.

Follow Up

Frequency & extent of follow-up will depend upon severity of disease

  • Monitor serum ALP every 3-6 months to determine the biochemical response to bisphosphonate therapy
    • Once the value of serum ALP plateaus after 3-6 months of assessment, it can be measured 1-2x/year as a marker of bone activity
  • A more specific bone formation/resorption marker other than ALP (ie amino-terminal propeptide of type 1 collagen [P1NP], βC-terminal propeptide of type-1 collagen [βCTx], N-terminal propeptide of type 1 collagen [NTx] assay) may be measured for patients w/ monostatic Paget’s disease
  • Serial imaging tests (eg bone scan) are not generally useful in routine monitoring of treatment response
    • Bone scan may be helpful in monitoring treatment response after 6-12 months of treatment in patients w/ monostotic disease
  • If treatment failure is apparent consider re-treatment 6 months after the initial therapy for the following:
    • Symptom relapse or persistence
    • >25% above nadir of serum ALP in asymptomatic patient
  • Long-term evolution increases the risk for osteosarcoma on pagetic bone
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Roshini Claire Anthony, 07 Nov 2017

Women who are underweight, particularly in their late teens and mid-thirties, may be at risk for early menopause, a recent study found. 

17 May 2017
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.
Audrey Abella, 20 Jan 2017
Diabetes was not a risk factor for total knee replacement (TKR) due to severe knee osteoarthritis, a Singapore study found.